Company Overview and News
HENRY SY, Sr. remains the country’s wealthiest man for the 11th straight year in Forbes Asia’s “Philippines’ 50 Richest” list, which reflected the economy’s overall volatility as many registered shifts in wealth from 2017.
ICT JGSMY GTCAP GTCXY SVTMF NIKL SMCP1 JGS SM ICTEF SECB SMGBF SMIVY SMC ALGGY SBS AGI JGSHF GMA7 SMGBY NIKAY SMC2B SMC2A SMC2D TECH SMC2C SMC2F SYBJF SMC2E ALGGF GNWKY LTG
Transmission superhighway operator National Grid Corp. of the Philippines (NGCP) has denied having discussions with Laguna-based electronics manufacturer Cirtek Holdings Philippines Corp. on using the national grid for mobile infrastructure.
GLO TECH NG GTMEY NGGTF GTMEF GLOPP GLOPA NGG
Laguna-based electronics manufacturer Cirtek Holdings Philippines Corp. is in talks with National Grid Corporation of the Philippines (NGCP) on a potential partnership that could transform the country’s electricity superhighway into a mobile backbone.
TECH NG NGGTF NGG
CIRTEK Holdings Philippines Corp. (CHPC) grew its net income by 14% in the first quarter of 2018, driven by a double-digit increase in revenues following the consolidation of its recently acquired firm alongside higher sales from its semiconductor unit.
PSKXF TECH PHSXY PSE
Cirtek Holdings Philippines Corp. (CHPC) grew its net income by 14% in the first quarter of 2018, driven by a double-digit increase in revenues following the consolidation of its recently acquired firm alongside higher sales in its semiconductor unit.
London’s venerable Financial Times (FT) recently released its first-ever “FT 1000 High-Growth Companies Asia-Pacific” list — with 26 Filipino firms making the grade, all of which are listed on the Philippine Stock Exchange except for one.
JGSMY CNPF JGS ATI SGI CEBUY TUGS ACR SSI JBFCF MWP PHSXY H2O LNSTY PSE MWIDE CEB AISNY JGSHF CIC PSKXF JBFCY PRGLY PGOLD MBC PGCMF CROWN TECH STI CEBUF SPC JFC PERC
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to PSE:TECH / Cirtek Holdings Philippines Corporation on message board site Silicon Investor.